tbuckley/cabot-search huggingface dataset:
A Novel Circulating Noncoding Small RNA for the Detection of Acute Myocarditis
Authors: Rafael Blanco-Domínguez, Raquel Sánchez-Díaz, Hortensia de la Fuente, Luis J. Jiménez-Borreguero, Adela Matesanz-Marín, Marta Relaño, Rosa Jiménez-Alejandre, Beatriz Linillos-Pradillo, Katerina Tsilingiri, María L. Martín-Mariscal, Laura Alonso-Herranz, Guillermo Moreno, Roberto Martín-Asenjo, Marcos M. García-Guimaraes, Katelyn A. Bruno, Esteban Dauden, Isidoro González-Álvaro, Luisa M. Villar-Guimerans, Amaia Martínez-León, Ane M. Salvador-Garicano, Sam A. Michelhaugh, Nasrien E. Ibrahim, James L. Januzzi, Jan Kottwitz, Sabino Iliceto, Mario Plebani, Cristina Basso, Anna Baritussio, Mara Seguso, Renzo Marcolongo, Mercedes Ricote, DeLisa Fairweather, Héctor Bueno, Leticia Fernández-Friera, Fernando Alfonso, Alida L.P. Caforio, Domingo A. Pascual-Figal, Bettina Heidecker, Thomas F. Lüscher, Saumya Das, Valentín Fuster, Borja Ibáñez, Francisco Sánchez-Madrid, Pilar Martín
Journal: New England Journal of Medicine (2021)

The diagnosis of acute myocarditis typically requires either endomyocardial biopsy (which is invasive) or cardiovascular magnetic resonance imaging (which is not universally available). Additional approaches to diagnosis are desirable. We sought to identify a novel microRNA for the diagnosis of acute myocarditis.To identify a microRNA specific for myocarditis, we performed microRNA microarray analyses and quantitative polymerase-chain-reaction (qPCR) assays in sorted CD4+ T cells and type 17 helper T (Th17) cells after inducing experimental autoimmune myocarditis or myocardial infarction in mice. We also performed qPCR in samples from coxsackievirus-induced myocarditis in mice. We then identified the human homologue for this microRNA and compared its expression in plasma obtained from patients with acute myocarditis with the expression in various controls.We confirmed that Th17 cells, which are characterized by the production of interleukin-17, are a characteristic feature of myocardial injury in the acute phase of myocarditis. The microRNA mmu-miR-721 was synthesized by Th17 cells and was present in the plasma of mice with acute autoimmune or viral myocarditis but not in those with acute myocardial infarction. The human homologue, designated hsa-miR-Chr8:96, was identified in four independent cohorts of patients with myocarditis. The area under the receiver-operating-characteristic curve for this novel microRNA for distinguishing patients with acute myocarditis from those with myocardial infarction was 0.927 (95% confidence interval, 0.879 to 0.975). The microRNA retained its diagnostic value in models after adjustment for age, sex, ejection fraction, and serum troponin level.After identifying a novel microRNA in mice and humans with myocarditis, we found that the human homologue (hsa-miR-Chr8:96) could be used to distinguish patients with myocarditis from those with myocardial infarction. (Funded by the Spanish Ministry of Science and Innovation and others.).
Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts
Authors: Chaya S. Moskowitz, Cécile M. Ronckers, Joanne F. Chou, Susan A. Smith, Danielle Novetsky Friedman, Dana Barnea, Judith L. Kok, Simone de Vries, Suzanne L. Wolden, Tara O. Henderson, Helena J. H. van der Pal, Leontien C. M. Kremer, Joseph P. Neglia, Lucie M. Turcotte, Rebecca M. Howell, Michael A. Arnold, Michael Schaapveld, Berthe Aleman, Cecile Janus, Birgitta Versluys, Wendy Leisenring, Charles A. Sklar, Colin B. Begg, Malcolm C. Pike, Gregory T. Armstrong, Leslie L. Robison, Flora E. van Leeuwen, Kevin C. Oeffinger
Journal: Journal of Clinical Oncology (2021)

Women treated with chest radiation for childhood cancer have one of the highest risks of breast cancer. Models producing personalized breast cancer risk estimates applicable to this population do not exist. We sought to develop and validate a breast cancer risk prediction model for childhood cancer survivors treated with chest radiation incorporating treatment-related factors, family history, and reproductive factors.Analyses were based on multinational cohorts of female 5-year survivors of cancer diagnosed younger than age 21 years and treated with chest radiation. Model derivation was based on 1,120 participants in the Childhood Cancer Survivor Study diagnosed between 1970 and 1986, with median attained age 42 years (range 20-64) and 242 with breast cancer. Model validation included 1,027 participants from three cohorts, with median age 32 years (range 20-66) and 105 with breast cancer.The model included current age, chest radiation field, whether chest radiation was delivered within 1 year of menarche, anthracycline exposure, age at menopause, and history of a first-degree relative with breast cancer. Ten-year risk estimates ranged from 2% to 23% for 30-year-old women (area under the curve, 0.63; 95% CI, 0.50 to 0.73) and from 5% to 34% for 40-year-old women (area under the curve, 0.67; 95% CI, 0.54 to 0.84). The highest risks were among premenopausal women older than age 40 years treated with mantle field radiation within a year of menarche who had a first-degree relative with breast cancer. It showed good calibration with an expected-to-observed ratio of the number of breast cancers of 0.92 (95% CI, 0.74 to 1.16).Breast cancer risk varies among childhood cancer survivors treated with chest radiation. Accurate risk prediction may aid in refining surveillance, counseling, and preventive strategies in this population.
POS1348 MORTALITY AND ITS RELATED FACTORS IN PATIENTS WITH IGG4-RELATED DISEASE: A JAPANESE SINGLE-CENTER STUDY
Authors: I. Mizushima, H. Kawahara, T. Yoshinobu, S. Shin, R. Hoshiba, R. Nishioka, T. Zoshima, S. Hara, Y. Suzuki, K. Ito, M. Kawano
Journal: Annals of the Rheumatic Diseases (2021)

Background: In recent years, IgG4-related disease (IgG4-RD) has become a widely recognized disorder. However, mortality and its related factors in this disease are not well known. Objectives: This study aimed to clarify mortality and its related factors in patients with IgG4-RD. Methods: We retrospectively reviewed the medical records of patients with IgG4-RD diagnosed by experts based on fulfillment of the Japanese comprehensive diagnostic criteria and/or the 2019 ACR/EULAR classification criteria for IgG4-RD at a single center in Japan. Using the collected data, we calculated the crude mortality rate and the standardized mortality ratio (SMR) using national Japan mortality statistics and investigated the cause of death. We performed Cox regression analyses to assess mortality-related factors. Results: A total of 179 patients with IgG4-RD were included: 124 were male (69.3%); the median age was 68 years (interquartile range [IQR] 60-75 years); and the median follow-up from diagnosis was 47 months (IQR 17-84). Ten patients (5.6%) in our cohort died during the follow-up period. Five died of malignancy, one of respiratory failure, two of infectious pneumonia, one of sudden cardiac event, and one of suspected aortic aneurysmal rupture. The crude mortality rate was 11.1 per 1,000 person-years. According to national Japan mortality statistics, 11.6 age- and sex-matched deaths were expected to occur within the follow-up period, resulting in a SMR of 0.86 (95% confidence interval [CI] 0.41-1.59). Univariate Cox regression analyses indicated that the number of affected organs at diagnosis (hazard ratio [HR] 1.45, 95% CI 1.02-2.05), serum creatinine levels at diagnosis (HR 1.82, 95% CI 1.06-3.12), and the presence of malignancy during the clinical course (HR 3.93, 95% CI 1.10-14.02) had a significant impact on the time to death, whereas the other factors including age at diagnosis and serum C-reactive protein and IgG4 levels at diagnosis did not. Conclusion: Our findings suggest that the mortality rate of patients with IgG4-RD does not significantly differ from that of the Japanese general population. Multi-organ involvement and renal dysfunction at diagnosis as well as malignancy during the clinical course may be associated with higher mortality. An appropriate clinical evaluation for the early detection of these risk factors is required at first diagnosis and during long-term follow-up. Disclosure of Interests: None declared
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
Authors: Amit Saxena, Allison Guttmann, Mala Masson, Mimi Y Kim, Rebecca H Haberman, Rochelle Castillo, Jose U Scher, Kristina K Deonaraine, Alexis J Engel, H Michael Belmont, Ashira D Blazer, Jill P Buyon, Ruth Fernandez-Ruiz, Peter M Izmirly, Samrachana Adhikari, Jordan Axelrad, Natalie Azar, Rebecca Blank, Lenore Brancato, Konstantin Brodetskiy, Lily Cao, Philip M. Carlucci, Steven Carsons, Miao Chang, Shannon Chang, Alan Chen, Michael Colin, Lauren Fried, Bruce Garner, Avram Goldberg, Brian Golden, Michael Golpanian, Mayce Haj-Ali, Jessica Hoey, Yamen Homsi, Simon Hong, David Hudesman, Nazia Hussain, Brian Jaros, Susan Katz, Avani Kolla, Euna Lee, Sicy Lee, Robert Lesser, Robin Lipschitz, Eileen Lydon, Fardina Malik, Keshav Mangalick, Kavini Mehta, Anang Modi, Andrea Neimann, Joshua Novack, Julie Nusbaum, Connor Peterson, Andres Piatti, Benjamin Plotz, Andrew Porges, Lindsey Quintana, Paula Rackoff, Deborah Ramirez, Lauren Rangel, Soumya Reddy, Kimberly Robins, Pamela Rosenthal, Jonathan Samuels, Sabina Sandigursky, Vaish Sekar, Shruti Shankar, Harry Shen, Stephen Smiles, Craig Smuda, Bruce Solitar, Gary Solomon, Jennifer Stein, Alexa Steuer, Janine Sullivan, Katerina Svigos, Andrea Troxel, Stelios Viennas, Lauren Wong, Di Yan, Kaitlyn (Lu) Yin, Trevor Young, Gary Zagon
Journal: The Lancet Rheumatology (2021)
POS0576 EFFECTS OF ACUTE EXERCISE ON SERUM BDNF LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: S. Baglan Yentur, Z. Ercan, G. Deniz, A. Karatas, M. Gur, G. Alkan, S. S. Koca
Journal: Annals of the Rheumatic Diseases (2021)

Background: Brain derived neurotrophic factor (BDNF) is a neurotrofic factor that may show healing, survival-promoting and protective effects on neurons in central and peripheral nervous system. The effect of physical exercise on serum BDNF is unclear. Also, BDNF level was found significantly lower in rheumatoid Arthritis (RA) patients with depression. Objectives: Aim of this study is to investigate the variation of BDNF levels following acute exercise and potential correlation between BDNF levels and depression. Methods: This study included 44 RA patients and 44 age and sex matched healthy controls (HC). Aerobic exercise was performed to all participants for a single session. The intervention was performed on a treadmill and included 5 minutes of warm-up, 20 minutes of walking exercise reaching at 60- 80% of Maximal heart rate and 5 minutes of cool-down. Depression and anxiety levels were evaluated with Beck Depression Inventory (BDI) and Hospital Anxiety and Depression Scale (HADS). Blood samples from all subjects were taken and centrifuged before and immediately after the exercise intervention. Results: Serum BDNF levels (both baseline and post-exercise) were similar in the RA and HC group (Table 1). Although after aerobic exercise serum BDNF levels were significantly decreased in both RA and HC groups (Wilcoxon Rank P &lt; 0.05) ΔBDNF levels was significantly higher in the RA group than HC group. Serum BDNF level was increased in 30.2% of healthy subjects and 4.5% of RA patients (P = 0.002). On the other hand, BDI, HADS depression and HADS anxiety indices were correlated significantly with ΔBDNF levels in the RA group (p&lt;0.05) but not in HC group. Conclusion: A single bout of exercise may be effective on serum BDNF levels in patients with RA and healthy subjects. However, psychological comorbidities affect the amelioration of BDNF level, in RA. The long-term effect of alterations on BDF level is candidate to evaluate by prospective studies. Table 1. Clinical and laboratory characteristics in the study groups RA (n=44) HC (n=44) P Mean age, years 46.8±10.3 43.4±6.4 0.071* Females, n (%) 32 (72.7) 31 (70.5) 0.813** Active smokers, n (%) 12 (27.3) 10 (22.7) 0.622** BMI, kg/m 2 26.8±4.6 25.6±2.4 0.127* HADS Depression 10.2±3.9 2.2±2.1 &lt;0.001* HADS Anxiety 10.4±4.1 2.4±2.1 &lt;0.001* BDI 17.9±8.1 3.7±4.1 &lt;0.001* BDNF (baseline), pg/ml 798.9±381.1 688.7±469.9 0.069*** BDNF (post-exercise), pg/ml 469.5±193.5 509.9±380.4 0.593*** ΔBDNF, pg/ml 329.5±258.4 211.1±302.6 0.047*** BDNF increased, n (%) 2 (4.5) 13 (30.2) 0.002** RA; rheumatoid arthritis, HC; healthy control, BMI; body mass index, HADS; Hospital Anxiety and Depression Scale, BDI; Beck Depression Inventory, BDNF; brain derived neurotrophic factor *Student’s t test, **Chi square test and ***Mann Whitney U test Disclosure of Interests: None declared
Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil
Authors: Vagner Fonseca, Ronaldo de Jesus, Talita Adelino, Alexandre Barbosa Reis, Breno Bernardes de Souza, Adriana Aparecida Ribeiro, Natália Rocha Guimarães, Miriam Teresinha Furlam Prado Livorati, Daniel Ferreira de Lima Neto, Rodrigo Bentes Kato, Layssa Miranda de Oliveira Portela, Leonardo Hermes Dutra, Carla Freitas, André Luiz de Abreu, Eduardo Regis Melo Filizzola, Arnaldo Correia de Medeiros, Felipe Campos de Melo Iani, Glauco Carvalho, José Lourenço, Tulio de Oliveira, Luiz Carlos Junior Alcantara, Marta Giovanetti
Journal: Journal of Infection (2021)
Abstract 16388: PRKCBP1 Regulates the HIF-1 Axis in the Heart
Authors: Kathryn J Schunke, Chad B Walton, Ralph V Shohet
Journal: Circulation (2018)

Introduction: PRKCBP1 is known to cooperatively bind to acetylated and methylated nucleosomes through its bromo- and PHD domains. It can modulate transcription and cancer progression by histone met...
Dose-Dependent Associations of Dietary Glycemic Index, Glycemic Load, and Fiber With 3-Year Weight Loss Maintenance and Glycemic Status in a High-Risk Population: A Secondary Analysis of the Diabetes Prevention Study PREVIEW
Authors: Ruixin Zhu, Thomas M. Larsen, Mikael Fogelholm, Sally D. Poppitt, Pia S. Vestentoft, Marta P. Silvestre, Elli Jalo, Santiago Navas-Carretero, Maija Huttunen-Lenz, Moira A. Taylor, Gareth Stratton, Nils Swindell, Mathijs Drummen, Tanja C. Adam, Christian Ritz, Jouko Sundvall, Liisa M. Valsta, Roslyn Muirhead, Shannon Brodie, Teodora Handjieva-Darlenska, Svetoslav Handjiev, J. Alfredo Martinez, Ian A. Macdonald, Margriet S. Westerterp-Plantenga, Jennie Brand-Miller, Anne Raben
Journal: Diabetes Care (2021)

To examine longitudinal and dose-dependent associations of dietary glycemic index (GI), glycemic load (GL), and fiber with body weight and glycemic status during 3-year weight loss maintenance (WLM) in adults at high risk of type 2 diabetes.In this secondary analysis we used pooled data from the PREVention of diabetes through lifestyle Intervention and population studies in Europe and around the World (PREVIEW) randomized controlled trial, which was designed to test the effects of four diet and physical activity interventions. A total of 1,279 participants with overweight or obesity (age 25-70 years and BMI ≥25 kg ⋅ m-2) and prediabetes at baseline were included. We used multiadjusted linear mixed models with repeated measurements to assess longitudinal and dose-dependent associations by merging the participants into one group and dividing them into GI, GL, and fiber tertiles, respectively.In the available-case analysis, each 10-unit increment in GI was associated with a greater regain of weight (0.46 kg ⋅ year-1; 95% CI 0.23, 0.68; P < 0.001) and increase in HbA1c. Each 20-unit increment in GL was associated with a greater regain of weight (0.49 kg ⋅ year-1; 0.24, 0.75; P < 0.001) and increase in HbA1c. The associations of GI and GL with HbA1c were independent of weight change. Compared with those in the lowest tertiles, participants in the highest GI and GL tertiles had significantly greater weight regain and increases in HbA1c. Fiber was inversely associated with increases in waist circumference, but the associations with weight regain and glycemic status did not remain robust in different analyses.Dietary GI and GL were positively associated with weight regain and deteriorating glycemic status. Stronger evidence on the role of fiber is needed.
BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases
Authors: Alok K. Singh, Mihai G. Netea, William R. Bishai
Journal: Journal of Clinical Investigation (2021)

First administered to a human subject as a tuberculosis (TB) vaccine on July 18, 1921, Bacillus Calmette-Guérin (BCG) has a long history of use for the prevention of TB and later the immunotherapy of bladder cancer. For TB prevention, BCG is given to infants born globally across over 180 countries and has been in use since the late 1920s. With about 352 million BCG doses procured annually and tens of billions of doses having been administered over the past century, it is estimated to be the most widely used vaccine in human history. While its roles for TB prevention and bladder cancer immunotherapy are widely appreciated, over the past century, BCG has been also studied for nontraditional purposes, which include (a) prevention of viral infections and nontuberculous mycobacterial infections, (b) cancer immunotherapy aside from bladder cancer, and (c) immunologic diseases, including multiple sclerosis, type 1 diabetes, and atopic diseases. The basis for these heterologous effects lies in the ability of BCG to alter immunologic set points via heterologous T cell immunity, as well as epigenetic and metabolomic changes in innate immune cells, a process called “trained immunity.” In this Review, we provide an overview of what is known regarding the trained immunity mechanism of heterologous protection, and we describe the current knowledge base for these nontraditional uses of BCG.
Late-Breaking Basic Science Abstracts From the American Heart Association’s Scientific Sessions 2020
Authors: Qiuyu M Zhu, Bryan MacDonald, Taiji Mizoguchi, Mark Chaffin, Alison Leed, Alessandro Arduini, Edyta Malolepsza, Kasper Lage, Virendar Kaushik, Sekar Kathiresan, Patrick T Ellinor, Massachusetts General Hosp, Cambridge, Broad Institute of MIT and Harvard, Cambridge, Verve therapeutics, Cambridge, Broad Institute, Cambridge, Verve Therapeutics, Cambridge, Massachusetts General Hosp, Boston
Journal: Circulation Research (2020)
AB0212 NON-ADHERENCE IN RHEUMATOLOGIC IMMUNE-MEDIATED DISEASES
Authors: A. Rodríguez-Alarcón, N. Carballo, L. Río, C. Pérez, E. González-Colominas, X. Duran, J. Monfort, S. Grau-Cerrato, O. Ferrández-Quirante
Journal: Annals of the Rheumatic Diseases (2021)

Background: Patient adherence is a key determinant of treatment success in rheumatologic immune-mediated diseases. Available data about adherence to biological treatments and factors associated to non-adherence is limited in Spain. Moreover, no studies compare adherence between subcutaneous and oral drugs. Objectives: To evaluate non-adherence to prescribed subcutaneous biologicals and oral drugs in patients with rheumatologic immune-mediated diseases and to assess possible predictor factors associated to treatment non-adherence. Methods: Retrospective observational study including all patients with oral and subcutaneous treatment for rheumatologic immune-mediated diseases from 2017 to 2019 in the outpatient pharmaceutical care area from a tertiary university hospital. Non-adherence was evaluated by reviewing all scheduled drug-dispensing visits in the computerized application. We considered non-adherent every time that a patient missed at least one drug administration. Data collected: demographic, total patients and patient-treatments, total dispensing visits and route of administration for drug dispensed in every visit. We classified patients in adherent and non-adherent considering dispensing visits. Non-adherent group: number of dispensing visits, reasons for non-adherence, number of missed administrations per patient and drug and predictor factors for non-adherence. Results: 783 patients included: 52.4(13.7) years; 427(54.5%) female; 164 (20.9%) smoker; 697 (89%) Caucasian. A total of 79 (10.1%) of 783 patients received more than one treatment. 869 patient-treatments: 294 adalimumab (33.8%), 236 etanercept (27.2%), 78 golimumab (8.9%), 47 apremilast (5.4%), 39 certolizumab (4.5%), 34 secukinumab (3.9%), 30 tocilizumab (3.5%). 9,197 dispensing visits. Route of administration: 6,406 subcutaneous (93.2%), 374 oral (6.8%). Non-adherence analysis: 2417 (26.3%) dispensing visits, reasons for non-adherence/ dispensing visits: 92 unjustified (97.5%), 33 infection (1.4%), 18 (surgery) 0.7%, 3 pregnancy (0.1%), 6 others (0.3%). Number of missed administrations/patient treatment: 675 patients missed at least one administration (77.7%).Mean 2.5 (±12.9) missed administrations. Number of missed administrations/drug: 9.9 baricitinib (±20.8), 15.8 tofacitinib (±31.2), 25.4 apremilast (±53.2). Predictor factors for non-adherence: ethnicity (p=0.015), treatment with golimumab (p=0.006), and tocilizumab (p=0.036). Age (p=0.072). Conclusion: - Non-adherence to the prescribed drug occurred in 77.7% of patients with rheumatologic immune-mediated diseases - Demographic factors such as ethnicity as well as golimumab and tocilizumab treatment, despite their different frequency of administration, were predictors for non-adherence - Route of administration did not influence non-adherence. Disclosure of Interests: None declared
The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation
Authors: Wenjie Zhang, Guangyan Zhangyuan, Fei Wang, Kangpeng Jin, Haiyuan Shen, Liansheng Zhang, Xiang Yuan, Jincheng Wang, Haitian Zhang, Weiwei Yu, Ruyi Huang, Xiaoliang Xu, Yin Yin, Guisheng Zhong, Anning Lin, Beicheng Sun
Journal: Immunity (2021)
Abstract #1303: Mre11 differentially regulates homologes recombination and single-strand annealing subpathways in the repair of DNA double-strand break
Authors: Liping Li, Fen Xia
Journal: Cancer Research (2009)

Purpose/Objectives: Mre11, in a complex with Rad50 and NBS1, is critical in maintaining genome stability. In addition to its function in checkpoint, Mre11 may also involve in the recombinational repair of DNA double-strand breaks (DSBs). Precise homologous recombinational repair (HR) and deletional single-strand annealing (SSA) are the two major recombinational repair subpathways. We hypothesize that Mre11 may regulate both HR and SSA processes. Materials/Methods: : 1) A single copy of SSA or HR reporter substrate with one I-SceI restriction endonuclease sites was stably integrated into the genome of human embryonic kidney (HEK) 293 cells. DNA DSBs were generated by transient expression of the I-SceI in HEK293. The HR- or SSA-mediated DSB repair events would restore GFP expression and were quantified by FACS analysis. 2) Mre11 expression was abolished using Mre11 siRNA. 3) Wildtype or mutant Mre11 which was siRNA-resistant were used in the SSA or HDR phonotypical rescue. 3) Cell cycle distribution and viability, which might influence repair processes, were also measured. Results: Mre11 knockdown resulted in a 1.8-fold decrease in HR (p  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1303.
Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation
Authors: Juliette Lambert, Jérôme Lambert, Xavier Thomas, Alice Marceau-Renaut, Aline Renneville, Marie-Magdelaine Coude, Sandrine Hayette, Christian Recher, Emmanuel Raffoux, Arnaud Pigneux, Céline Berthon, Christine Terré, Karine Celli-Lebras, Sylvie Castaigne, Nicolas Boissel, Philippe Rousselot, Herve Dombret, Claude Preudhomme
Journal: Blood (2017)